Brazil Approves BridgeBio's BEYONTTRA for ATTR-CM, Expanding Global Commercial Reach
BBIO has more than doubled off its 52-week low of $31.77.
Summary
Brazil's ANVISA has granted marketing authorization for BridgeBio Pharma's BEYONTTRA (acoramidis) to treat ATTR-CM. This approval expands the commercial footprint of a key product for BridgeBio into a significant new market, following previous approvals in the U.S., EU, UK, Switzerland, and Japan, as highlighted in the company's recent 10-K. Acoramidis, a near-complete TTR stabilizer, demonstrated strong efficacy in the Phase 3 ATTRibute-CM study, including a 42% reduction in composite cardiovascular events. This development is a positive catalyst, opening a new revenue stream for the company. Commercialization efforts in Brazil are anticipated to commence in the second half of 2026, and investors will be watching for initial sales performance.
At the time of this announcement, BBIO was trading at $70.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.5B. The 52-week trading range was $31.77 to $84.94. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.